Drug Profile
CNTX 6016
Alternative Names: CNTX-6016Latest Information Update: 13 Nov 2023
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim
- Developer Centrexion Therapeutics
- Class Non-opioid analgesics
- Mechanism of Action Cannabinoid receptor CB2 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Neuropathic pain
Most Recent Events
- 30 Aug 2023 Centrexion Therapeutics completes a phase I trial in Neuropathic pain in USA (PO, Capsule) (NCT04857957)
- 14 Apr 2021 Phase-I clinical trials in Neuropathic pain in USA (PO) (NCT04857957)
- 04 Sep 2019 Pharmacodynamics data from preclinical studies in Neuropathic pain released by Centrexion Therapeutics